Back to CJC-1295 with DAC product page
Reference Scope
The citations below are provided to document how CJC-1295 DAC appears in published analytical and receptor-pathway literature. Summaries are limited to study context, compound identity, and documentation value so the page stays aligned with research-use-only catalog hygiene.
Controlled Receptor-Pathway Characterization
Peer-reviewed literature describes CJC-1295 DAC as a long-profile GHRH receptor analog used in controlled research settings to characterize receptor-axis biomarkers and albumin-binding behavior. The product listing should be read only as a research-material catalog entry with batch-specific documentation.
Source: Teichman SL, Neale A, Lawrence B, Gagnon C, Caber JP, Bhatt RS. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PubMed PMID: 16352683
GHRH Receptor Signaling Models
Additional receptor-pathway work discusses CJC-1295 DAC in relation to GHRH-axis signaling patterns under controlled research conditions. The relevance for this catalog page is classification as a synthetic receptor-pathway reference material, not expected outcome or application.
Source: Ionescu M, Frohman LA. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702. PubMed PMID: 17018654
Model-System Literature
Published model-system literature has used CJC-1295 DAC to study GHRH-receptor pathway behavior in controlled experimental contexts. This literature is cited here for background and compound classification only.
Source: Alba M, Fintini D, Bowers CY, Parlow AF, Salvatori R. American Journal of Physiology – Endocrinology and Metabolism. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00172.2006. PubMed PMID: 16822960
Analytical Characterization
Analytical references provide structural and detection-oriented context for CJC-1295 DAC, including the DAC modification and laboratory identification methods. These references support chemical-identity documentation and should not be read as use guidance.
Source: Thomas A, Kohler M, Schanzer W, et al. Drug Testing and Analysis. 2011;3(9):647-652. doi:10.1002/dta.233. PubMed PMID: 21204297
Limitations and Current Knowledge Gaps
The research summarized on this page reflects findings from preclinical models (primarily rodent and in vitro studies). Several important limitations should be acknowledged when evaluating this evidence:
- Lack of human clinical trials: No large-scale, randomized controlled trials in humans have been completed for most research peptides, including CJC-1295 DAC Literature Reference. Animal data does not directly translate to human outcomes.
- Dosing uncertainty: There are no standardized, clinically validated dosing protocols. Doses used in animal studies may not be relevant to human applications.
- Unknown long-term safety profile: Long-term toxicity, chronic administration effects, and potential off-target biological interactions remain unstudied.
- Regulatory status: CJC-1295 DAC Literature Reference is not approved by the FDA or other major regulatory agencies for human therapeutic use. Regulatory classification varies by jurisdiction.
- Publication bias: Positive results are more likely to be published than negative findings, which may inflate the apparent strength of evidence.
Researchers should evaluate these findings in context and avoid extrapolating preclinical results to clinical recommendations.